Compare Ascendis Pharma A/S (ASND) vs Fabrinet (FN) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Fabrinet (FN) trades at $471.13, down 2.41% over 24 hours, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, with Q1 2026 EPS of $3.72 beating estimates of $3.56, continuing a pattern of earnings outperformance. Revenue growth is robust, projected to rise from $3.42B in 2025 to $4.2B in 2026, while net income margin improves to 9.94%. Analyst sentiment remains highly bullish with a consensus price target of $733.00, though the stock faces near-term technical headwinds and premium valuation multiples.

Fabrinet's outlook is supported by its strategic position in the AI optical supply chain and consistent earnings beats, offering significant upside relative to analyst targets. Key risks include high valuation metrics, datacom supply constraints, and foreign exchange exposure. The stock presents a compelling growth opportunity for investors comfortable with its premium pricing, provided operational execution remains strong amid competitive and macroeconomic challenges.